{"id":8503,"date":"2022-12-14T09:23:30","date_gmt":"2022-12-14T07:23:30","guid":{"rendered":"https:\/\/covid-19-bilgi.de\/?page_id=8503"},"modified":"2022-12-14T09:34:58","modified_gmt":"2022-12-14T07:34:58","slug":"test","status":"publish","type":"page","link":"https:\/\/covid-19-bilgi.de\/tr\/test\/","title":{"rendered":"G\u00fc\u00e7lendirici A\u015f\u0131 bis 121222"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t

COVID-19'a Kar\u015f\u0131 Hat\u0131rlatma A\u015f\u0131s\u0131 <\/h2>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t

G\u00fc\u00e7lendirici A\u015f\u0131<\/h1>\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

Daimi A\u015f\u0131 Komisyonu (STIKO), ikinci a\u015f\u0131lar\u0131n\u0131 alt\u0131 ay veya daha \u00f6nce yapt\u0131ran 18 ya\u015f ve \u00fczerindeki t\u00fcm vatanda\u015flara COVID-19’a kar\u015f\u0131 \u00a0hat\u0131rlatma (tazeleme) a\u015f\u0131s\u0131 yani g\u00fc\u00e7lendirici a\u015f\u0131 \u00f6nermektedir. Eyl\u00fcl ay\u0131ndan beri, belirli insan gruplar\u0131na \u00f6ncelikli g\u00fc\u00e7lendirici a\u015f\u0131 yap\u0131lmaktad\u0131r. G\u00fc\u00e7lendirici a\u015f\u0131 ile ilgili t\u00fcm bilgileri burada bulabilirsiniz.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131 neden gereklidir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
Korona a\u015f\u0131s\u0131, ciddi ve \u00f6l\u00fcmc\u00fcl hastal\u0131k s\u00fcre\u00e7lerine kar\u015f\u0131 etkili bir koruma sa\u011flamakta ve yo\u011fun bak\u0131m \u00fcnitesinde tedavi edilmesi gereken COVID-19 vakalar\u0131n\u0131n say\u0131s\u0131n\u0131 \u00f6nemli \u00f6l\u00e7\u00fcde azalmaktad\u0131r. Ancak bilimsel bulgular, COVID-19 a\u015f\u0131lar\u0131na kar\u015f\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k tepkisinin belirli insan gruplar\u0131nda daha zay\u0131f oldu\u011funu veya daha \u00e7abuk azald\u0131\u011f\u0131n\u0131 g\u00f6stermektedir. \u00d6zellikle savunmas\u0131z olan bu gruplar\u0131 a\u011f\u0131r COVID-19 hastal\u0131\u011f\u0131 gidi\u015fat\u0131ndan korumaya devam etmek i\u00e7in g\u00fc\u00e7lendirici a\u015f\u0131 yap\u0131lmas\u0131 \u00f6nerilir.<\/span><\/div>
\u00a0<\/div>

Hedef, m\u00fcmk\u00fcn oldu\u011funca \u00e7ok say\u0131da \u015fiddetli COVID-19 (hastaneye yat\u0131\u015f, \u00f6l\u00fcm) seyrini \u00f6nlemek ve \u00a0tamamlanm\u0131\u015f temel COVID-19 a\u015f\u0131lar\u0131 sonras\u0131 ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi azalm\u0131\u015f veya h\u0131zla azalan ki\u015filere koruyucu sa\u011fl\u0131k bak\u0131m\u0131 anlam\u0131nda koruyucu nedenlerden dolay g\u00fc\u00e7lendirici a\u015f\u0131lar teklif edilir veya etkinle\u015ftirilir.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131lar hangileridir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131, onaylanm\u0131\u015f bir mRNA a\u015f\u0131s\u0131n\u0131n bir dozunun yeniden uygulanmas\u0131d\u0131r. \u00a02 A\u011fustos 2021’de Sa\u011fl\u0131k Bakanlar\u0131 Konferans\u0131 (GMK) taraf\u0131ndan belirli insan gruplar\u0131 i\u00e7in g\u00fc\u00e7lendirici a\u015f\u0131lar\u0131n kullan\u0131lmas\u0131na karar verildi.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Temel a\u015f\u0131laman\u0131n optimizasyonu, \u00fc\u00e7\u00fcnc\u00fc a\u015f\u0131lama, hat\u0131rlatma a\u015f\u0131s\u0131 ve g\u00fc\u00e7lendirici a\u015f\u0131 aras\u0131ndaki fark nedir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Temel ba\u011f\u0131\u015f\u0131klama genellikle COVID-19’a kar\u015f\u0131 ba\u011f\u0131\u015f\u0131klama anlam\u0131na gelir; \u00f6rne\u011fin, onaylar\u0131na g\u00f6re bir (Johnson & Johnson’dan Janssen\u00ae) veya iki a\u015f\u0131 (BioNTech \/ Pfizer’den Comirnaty\u00ae veya Moderna’dan Spikevax\u00ae (Vaccine Moderna) veya AstraZeneca’dan Vaxzevria\u00ae).<\/p>

E\u011fer temel a\u015f\u0131lama yeterli de\u011filse, temel a\u015f\u0131lamay\u0131 optimize etmek i\u00e7in \u00fc\u00e7\u00fcnc\u00fc bir a\u015f\u0131 veya ba\u015fka bir a\u015f\u0131 kullan\u0131l\u0131r. Bu, \u00f6rne\u011fin organ nakli gibi ciddi ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filer veya temel a\u015f\u0131 i\u00e7in Johnson & Johnson’dan tek doz Janssen\u00ae alm\u0131\u015f ki\u015filer i\u00e7in ge\u00e7erlidir. Bu durumda, \u00fc\u00e7\u00fcnc\u00fc a\u015f\u0131lama, ilk a\u015f\u0131lamadan d\u00f6rt hafta sonra m\u00fcmk\u00fcnd\u00fcr.<\/span><\/div>
\u00a0<\/div>

Hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131, azalan bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisini tekrar art\u0131rmak i\u00e7in yap\u0131lan yeni bir a\u015f\u0131d\u0131r. Bu, \u00f6rne\u011fin tetanoz veya \u00e7ocuk felci gibi \u00e7e\u015fitli bakteriyel veya viral patojenler i\u00e7in sabit zaman aral\u0131klar\u0131nda zaten bilinmektedir, b\u00f6ylece a\u015f\u0131 korumas\u0131 korunur. Korona a\u015f\u0131s\u0131 durumunda, hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131, tam bir temel a\u015f\u0131lama seriden sonra bir mRNA a\u015f\u0131s\u0131n\u0131n bir dozunun yeniden uygulanmas\u0131 anlam\u0131na gelir. Uzun vadede a\u015f\u0131 korumas\u0131n\u0131 s\u00fcrd\u00fcrmeye hizmet eder. Bu COVID-19 a\u015f\u0131s\u0131, genellikle temel a\u015f\u0131lamadan alt\u0131 ay sonra yenilenmelidir.<\/p>

G\u00fc\u00e7lendirici (Booster) a\u015f\u0131, hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131n\u0131n e\u015f anlam\u0131d\u0131r. “Booster” terimi \u0130ngilizce’den gelir ve anlam\u0131 “g\u00fc\u00e7lendirici” dir.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fc\u00e7lendirici a\u015f\u0131n\u0131n amac\u0131 nedir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Sonbahar ve k\u0131\u015f aylar\u0131nda m\u00fcmk\u00fcn olan en iyi korumay\u0131 sa\u011flamak amac\u0131yla, COVID-19’a kar\u015f\u0131 a\u015f\u0131 kampanyas\u0131na devam etmek b\u00fcy\u00fck \u00f6nem ta\u015f\u0131maktad\u0131r. Ama\u00e7, pandeminin mevcut bu a\u015famas\u0131nda, daha \u00f6nce a\u015f\u0131lanmam\u0131\u015f ki\u015filer i\u00e7in acilen ihtiya\u00e7 duyulan a\u015f\u0131lara ek olarak \u00f6zellikle hat\u0131rlatma \u00a0(tazeleme) a\u015f\u0131s\u0131 \u00a0– yani g\u00fc\u00e7lendirici a\u015f\u0131 – ile pandeminin daha fazla kontrol alt\u0131na al\u0131nmas\u0131na \u00f6nemli katk\u0131 sa\u011flamakt\u0131r.<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

Kimlere g\u00fc\u00e7lendirici a\u015f\u0131 olmas\u0131 \u00f6nerilmektedir?<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t

STIKO, 18 ya\u015f ve \u00fcst\u00fc t\u00fcm vatanda\u015flara COVID-19 g\u00fc\u00e7lendirici a\u015f\u0131 \u00f6nermektedir.<\/strong><\/p>

Daimi A\u015f\u0131 Komisyonu (STIKO), ikinci a\u015f\u0131lar\u0131n\u0131 alt\u0131 ay veya daha \u00f6nce yapt\u0131ran 18 ya\u015f ve \u00fczerindeki t\u00fcm vatanda\u015flara COVID-19’a kar\u015f\u0131 tazeleme (hat\u0131rlatma) a\u015f\u0131s\u0131 yani g\u00fc\u00e7lendirici a\u015f\u0131 \u00f6nermektedir. Bununla birlikte Daimi A\u015f\u0131 komisyonu STIKO, \u00f6zellikle ba\u011f\u0131\u015f\u0131kl\u0131k yetmezli\u011fi olan ki\u015filer, 70 ya\u015f ve \u00fcst\u00fc ki\u015filer ve ya\u015fl\u0131lara bak\u0131m veren tesislerde ikamet edenler i\u00e7in \u00f6ncelikli g\u00fc\u00e7lendirici a\u015f\u0131 yap\u0131lmas\u0131 tavsiyesini yinelemektedir.\u00a0Temel ba\u011f\u0131\u015f\u0131klaman\u0131n sa\u011flad\u0131\u011f\u0131 koruma – \u00f6zellikle ya\u015fl\u0131l\u0131kta – zamanla azald\u0131\u011f\u0131ndan ve SARS-CoV-2’nin bask\u0131n delta varyant\u0131 nedeniyle \u015fiddetli COVID-19 seyrinin \u00f6nlenmesi i\u00e7in iyi bir ba\u011f\u0131\u015f\u0131kl\u0131k tepkisi gereklidir.<\/p>

Johnson & Johnson’\u0131n Janssen\u00ae a\u015f\u0131s\u0131 ile a\u015f\u0131lanm\u0131\u015f ki\u015filer, a\u015f\u0131lamadan d\u00f6rt hafta sonra temel a\u015f\u0131laman\u0131n optimizasyonunu almal\u0131d\u0131r.<\/span><\/div>
\u00a0<\/div><\/div>

STIKO ayr\u0131ca t\u0131bbi tesislerdeki personel, bak\u0131m personeli ve bak\u0131m tesislerinde \u00e7al\u0131\u015fan di\u011fer ki\u015filer i\u00e7in g\u00fc\u00e7lendirici a\u015f\u0131lar \u00f6nermektedir, \u00e7\u00fcnk\u00fc orada hem savunmas\u0131z ki\u015filerin oran\u0131 hem de enfeksiyon riski y\u00fcksektir ve SARS-CoV-2’nin bula\u015fmas\u0131ndan \u00a0mutlak ka\u00e7\u0131n\u0131lmal\u0131d\u0131r.<\/p><\/div>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t

G\u00fcncellik: 12.2021,<\/em> Kaynak: Bundesministerium f\u00fcr Gesundheit<\/p>\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

COVID-19’a Kar\u015f\u0131 Hat\u0131rlatma A\u015f\u0131s\u0131 G\u00fc\u00e7lendirici A\u015f\u0131 Daimi A\u015f\u0131 Komisyonu (STIKO), ikinci a\u015f\u0131lar\u0131n\u0131 alt\u0131 ay veya daha \u00f6nce yapt\u0131ran 18 ya\u015f ve \u00fczerindeki t\u00fcm vatanda\u015flara COVID-19’a kar\u015f\u0131 \u00a0hat\u0131rlatma (tazeleme) a\u015f\u0131s\u0131 yani g\u00fc\u00e7lendirici a\u015f\u0131 \u00f6nermektedir. Eyl\u00fcl ay\u0131ndan beri, belirli insan gruplar\u0131na \u00f6ncelikli g\u00fc\u00e7lendirici a\u015f\u0131 yap\u0131lmaktad\u0131r. G\u00fc\u00e7lendirici a\u015f\u0131 ile ilgili t\u00fcm bilgileri burada bulabilirsiniz. G\u00fc\u00e7lendirici a\u015f\u0131 neden gereklidir? […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/8503"}],"collection":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/comments?post=8503"}],"version-history":[{"count":5,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/8503\/revisions"}],"predecessor-version":[{"id":8509,"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/pages\/8503\/revisions\/8509"}],"wp:attachment":[{"href":"https:\/\/covid-19-bilgi.de\/tr\/wp-json\/wp\/v2\/media?parent=8503"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}